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Abstract
Mastitis, inflammation of the bovine mammary gland, is generally caused by intramammary
infection with bacteria, and antimicrobials have long been a corner stone of mastitis control.
As societal concern about antimicrobial use in animal agriculture grows, there is pressure to
reduce antimicrobial use in dairy farming. Point-of-care tests for on-farm use are increasingly
available as tools to support this. In this Research Reflection, we consider available culture-
dependent and culture-independent tests in the context of ASSURED criteria for low-resource
settings, including convenience criteria, scientific criteria and societal criteria that can be used
to evaluate test performance. As tests become more sophisticated and sensitive, we may be gen-
erating more data than we need. Special attention is given to the relationship between test out-
comes and treatment decisions, including issues of diagnostic refinement, antimicrobial
susceptibility testing, and detection of viable organisms. In addition, we explore the role of tech-
nology, big data and people in improved performance and uptake of point-of-care tests, recog-
nising that societal barriers may limit uptake of available or future tests. Finally, we propose that
the 3Rs of reduction, refinement and replacement, which have been used in an animal welfare
context for many years, could be applied to antimicrobial use for mastitis control on dairy farms.
Setting the scene: background and aim
Mastitis is an inflammation of the mammary gland, frequently caused by intramammary
infections (IMI), and occasionally by mechanical or chemical trauma (through teat or
udder trampling for instance), or when cleaning liquids are mistaken for teat disinfectants.
Mastitis and IMI are different biological processes that require different diagnostic tools and
treatments. Mastitis is characterised by physical and chemical changes in milk and, in mod-
erate or severe cases, by pathological changes in the mammary gland or systemically.
Clinical mastitis (CM) can be detected using human senses (vision, touch, and taste, although
the latter is discouraged), whereas detection of subclinical mastitis (SCM) requires additional
tools. With no one-to-one relationship between clinical severity and causative agent, the cause
of mastitis can rarely be detected without further testing. Ideally, mastitis treatment is based on
knowledge of severity, causative agent and prognosis so that anti-inflammatory, antimicrobial
and supportive treatments can be selected for maximum efficacy and minimal side effects,
which include potential selection for antimicrobial resistance (AMR). The contribution of
antimicrobial use (AMU) to selection for AMR has become of concern due to actual or pre-
dicted adverse effects in human and veterinary health (O’Neill, 2016). Both quantity and ‘qual-
ity’ (or type) of antimicrobials are important. The World Health Organization (WHO) has
identified Highest Priority Critically Important Antimicrobials (HP-CIA) for human medicine
(WHO, 2019), and suggested that HP-CIA ‘should not be used for treatment of food-
producing animals with a clinically diagnosed infectious disease’ (WHO, 2017). Quinolones,
macrolides and ketolides, polymixins and 3rd and 4th generation cephalosporins are all
HP-CIA used for mastitis treatment and we can do better in this area (Turner et al., 2018;
Doehring and Sundrum, 2019).
Selective treatment is the practice of restricting AMU to cases most likely to benefit from
treatment and may help to reduce AMU. The phrase ‘targeted treatment’ is also used and hints
at a different underlying philosophy. ‘Selective treatment’ suggests blanket treatment as the
default option, which is modified by selecting cows for treatment. Targeted treatment suggests
no treatment to be the default option, with targeting of treatment to those cows that are most
likely to benefit. Whilst selective dry cow treatment has been or become the norm in several
countries (Vanhoudt et al., 2018), selective treatment of lactational mastitis is a more recent
development (Lago and Godden, 2018). Principles underpinning this approach include the
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S002202992000062X
Downloaded from https://www.cambridge.org/core. University of Glasgow Library, on 04 Aug 2020 at 15:35:01, subject to the Cambridge Core terms of use, available at
notion that AMU must be reduced in livestock; the suggestion
that HP-CIA should be avoided in veterinary medicine; the recog-
nition that mild to moderate CM caused by gram-negative patho-
gens does not necessarily need antimicrobial treatment; evidence
that narrow-spectrum antimicrobials are effective against most
gram-positive mastitis; and the maxim that ‘lack of an indication
is a contra-indication’, whereby absence of viable bacteria may be
interpreted as lack of an indication. Each of these principles is
subject to debate, to individual differences in weighing of available
evidence, and to technical or societal opportunities and con-
straints, which explains the wide range of AMU practices on
dairy farms. Central to targeted treatment of lactational CM is
the ability to differentiate mild-to-moderate gram-positive mas-
titis from other forms of mastitis. Point-of-care (POC) testing
can make this distinction. For the sake of this paper, we interpret
‘point-of-care’ as a tool to inform treatment decisions. Generally,
this requires on-farm testing, although some commercial diagnos-
tic laboratories or veterinary practices may offer a 24-h turn-
around time (TAT) or service.
In this paper, we reflect on characteristics of POC tests with a
focus on CM diagnostics that can inform treatment decisions.
Specifically, we focus on how such tests succeed or fail in addres-
sing professional and societal needs, and how future develop-
ments might change this.
What do we need?
We need to detect CM cases, which is usually done during milk-
ing, by people or by equipment (reviewed by Hogeveen et al.,
2010). Where broad-spectrum antimicrobials are advocated for
treatment of CM, one could argue that there is no need for further
diagnostics. To reduce AMU, however, treatment would need to
be targeted to a subset of CM cases based on severity and causa-
tive agent. In addition to reduction in AMU, refinement may be
possible, e.g. by avoidance of HP-CIA antimicrobials, by use of
narrow-spectrum antimicrobials, or possibly based on antimicro-
bial susceptibility of pathogens. Many professionals and scientists
accept that pathogens such as Mycoplasma spp. and non-bacterial
organisms such as algae, (Prototheca spp.) and yeast (e.g. Candida
spp.) will not respond to antimicrobial treatment and that mild to
moderate gram-negative mastitis does not need to be treated with
antimicrobials (Lago and Godden, 2018). Some will also argue
that culture-negative mastitis cases are unlikely to respond to anti-
microbial treatment because there are no viable bacteria to treat,
whereas others emphasise that culture results may be false nega-
tive. Conversely, detection of gram-positive bacteria is not neces-
sarily indicative of IMI as it may result from contamination of
samples or tests, or from presence of clinically non-significant
organisms (Nyman et al., 2016). Here, we discuss ways to assess
diagnostic test performance in relation to diagnostic needs before
presenting detail of available tests in subsequent sections.
Convenience criteria
In terms of diagnostic capability, farms are resource-constrained set-
tings. To evaluate POC test performance in resource-constrained
human health care settings, The ASSURED criteria (Affordable,
Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free
and Deliverable to end-users) were developed (Kosack et al., 2017).
They capture scientific criteria (sensitivity, specificity) and conveni-
ence criteria (‘cheap’, ‘easy’, ‘quick’), and will be used here as frame-
work for discussion of POC tests for CM.
Dairy production is a sector which often has low profit margins,
which might seem to argue for tests with low costs, but price is not
necessarily a priority (Griffioen et al., 2016). Cost may need to be
balanced against ease of use, whereby some of the cheapest systems
may require significant user training and hence staff retainment.
More expensive systems may have higher ease of use due to auto-
mated sample processing, reading or interpretation and may be
more robust to changes in environment or personnel. There may
also be trade-offs between cost and time. For example, culture-
based diagnostics inherently have a slow turn-around due to the
time needed for bacterial growth, but they can be very affordable.
Conversely, currently available DNA-based diagnostics are fast
but require expensive instrumentation. The relative costs of
reagents, equipment and labour may be quite different between
countries, a phenomenon that is also reflected in the predominance
of milking systems (hand milking, milking parlour, or automated
milking system) in different parts of the world. Whether low-tech
or high-tech, good diagnostic tests cannot compensate for poor
quality samples. Any test applied to a contaminated sample is a
waste of resources. Surprisingly, not every POC test has ‘contamin-
ation’ as a recognised outcome. This may mask the presence of
false positives and give high test sensitivity at the expense of test
specificity, potentially leading to ‘justification’ of AMU based on
detection of contaminants rather than mastitis pathogens. Sample
quality, although rarely discussed, may be more important than
test characteristics.
Scientific criteria
Diagnostic tests are routinely judged based on the scientific criteria
of sensitivity (‘ability to recognise positives’) and specificity (‘ability
to recognise negatives’). Tests should be validated in the host species
and under the conditions where they are intended to be applied but
most published POC test evaluations are laboratory-based rather
than farm-based (online Supplementary Table S1). Estimates of sci-
entific criteria are often obtained by comparing the test results with
a reference test or ‘gold standard’. Because no test is perfect, no-gold
standard comparison or latent class analysis is also used (Nyman
et al., 2016). Outcomes of interest can be presence vs. absence or
quantitative thresholds, such as counts of colony forming units in
plate-based tests, Ct values in PCR-based analysis, or optical density
in colorimetric analyses. When comparing test characteristics across
studies, critical interpretation of the results is required as study
designs (e.g. definitions, reference tests, thresholds used), study
populations (animal and pathogen populations), and methods to
calculate confidence intervals may vary and make estimates for sci-
entific criteria study-specific. The summary of POC tests provided
in the online Supplementary Table S1 should be read with those
cautionary notes in mind. For on-farm application, predictive values
are more important than sensitivity and specificity, but they are
rarely reported because they are dependent on pathogen prevalence
and hence population-specific. A high positive predictive value
means that no unnecessary treatment is given (‘treat as little as pos-
sible’), which achieves the aim of reducing AMU, whereas a high
negative predictive value means that treatment is only withheld
when cows truly do not need it (‘treat as much as needed’), so
that cow welfare is not compromised.
Level of differentiation
A crucial question is how POC test results inform decision mak-
ing. Several plate-based assays have been developed to identify
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mastitis pathogens to species or genus level (see section What do
we have?), but the rationale for use of selective treatment for mild
to moderate CM is largely based on differentiation of gram-
positive vs. other forms of mastitis. Hence, one could argue that
a POC test only needs to give information about presence of
gram-positive organism. In addition, it needs to distinguish
between contamination and IMI. If genus or species level infor-
mation influences treatment decisions, however, for example by
differentiating Streptococcus spp. from Staphylococcus aureus or
S. aureus from non-aureus Staphylococci, this is relevant at
POC level. In some countries, narrow spectrum penicillins are
the 1st line of treatment for CM, in which case differentiation of
penicillin-susceptible and penicillin-resistant isolates may be use-
ful, particularly for S. aureus (Barkema et al., 2006). Some POC
tests now include antimicrobial susceptibility testing (Jones
et al., 2019). When susceptibility testing is conducted at sample
level rather than isolate level, without the ability to differentiate
between pure cultures, mixed cultures and contamination, the
value of such testing to inform treatment decisions is unknown.
In addition, its value may differ between farming systems and
regions. For example, predominance of Strep. uberis without pres-
ence of Escherichia coli as a major cause of CM is uniquely asso-
ciated with the pasture-based system in New Zealand and
predictive values from that system may not translate to other
dairy-production systems or regions (Bates et al., 2020). A recent
study suggested a 24% reduction of AMU could be achieved when
using a POC test with susceptibility testing, yet no change in milk
withhold was observed, which is surprising as milk of treated cows
should be withheld (Bates et al., 2020).
Societal criteria
Like convenience criteria (cost vs. ease of use) or scientific criteria
(sensitivity vs. specificity), societal drivers for POC test use may
be at odds with each other. For animal welfare reasons, a ‘security
blanket’ of broad-spectrum antimicrobials for all CM cases may
be preferred, but this does not sit well with calls to reduce and
refine AMU. From an economic point of view, the value of diag-
nostic tests is situation-specific. Like predictive values, the value of
information depends on pathogen prevalence. If most CM is
caused by a single species, the cost of testing may not be out-
weighed by its financial benefits (Cha et al., 2016). This line of
reasoning does not account for the potential introduction of
AMU quota, which, like milk quota, extend the impact of deci-
sions at individual level to other cows in the herd.
Societal concerns may also exist around work health and
safety. On-farm bacteriology by non-experienced people is forbid-
den is some countries because of concerns about propagating
pathogens, including hazard group 2 pathogens which can infect
and kill people. Several major mastitis pathogens belong to this
category, including E. coli, Klebsiella spp., S. aureus, and
Streptococcus agalactiae (Zadoks et al., 2011). In addition to con-
cerns about hazardous waste, environmental implications of POC
testing may need to be considered. Ideally, POC tests would use
materials that are bio-degradable or come from renewable sources.
What do we have?
We currently have POC tests that detect mastitis (inflammation) or
pathogen presence (Adkins and Middleton, 2018). Inflammation
is an indirect measure of infection whereas pathogen detection is
a direct measure of infection, with the caveat that pathogen
detection without evidence of inflammation may not be sufficient
evidence for IMI nor adequate justification for AMU (Nyman
et al., 2016). All currently available on-farm diagnostics for patho-
gen identification are culture based (online Supplementary
Table S1), whilst culture-independent methods are available off-
farm or underdevelopment for on-farm use.
Culture-dependent pathogen information
Several formats are available for culture-based POC tests, includ-
ing petrifilm, agar plates, and tube-based systems. Some
identify bacteria as gram-positive, gram-negative, or absent, e.g.
MastDecide, Petrifilm, Point-of-Cow, and VétoSlide. Others iden-
tify bacteria to genus and species-level, e.g. VétoRapid, Minnesota
Easy Culture Tri-plate, Accumast, SSGN plate, Hardy Diagnosis
Triplate, Micromast, Dip-Slide Mastitis, Selma and Selma Plus.
Some assays include antibiotic susceptibility testing, e.g.
Mastatest, Point-of-Cow and Speed Mam colour. All tests are
more reliable when used for diagnosis of broad categories
(growth, gram-positive, gram-negative) than at genus or species
level (Lago and Godden, 2018). Broad categories may suffice to
inform treatment decisions but for culling decisions, more detail
or accuracy can be desirable. For such decisions, however, TAT
is often less critical, and laboratory-based testing may be more
appropriate than on-farm testing.
Reported sensitivities for gram-positive bacteria range from
58.6% (MastDecide; Leimbach and Krömker, 2018) to 98%
(Minnesota easy culture system Bi-plate; McCarron et al.,
2009a), and specificities from 48% (Petrifilm; MacDonald, 2011)
to 97% (MastDecide). The inherent trade-off between sensitivity
and specificity tends to limit accuracy, although exceptions
exist, e.g. for E. coli (online Supplementary Table S1). Low
pathogen prevalence in POC test evaluation studies will result
in wide confidence intervals around point estimates for test char-
acteristics. Interestingly, Strep. agalactiae is a major pathogen in
many emerging dairy industries but almost no information is
available on accuracy of POC tests for this organism (online
Supplementary Table S1). The market that is currently targeted
for POC testing presumes a certain standard of farm manage-
ment, which would generally be associated with successful control
of Strep. agalactiae. Accuracy also depends on observer skills. For
example, the ability to detect S. aureus based on haemolysis
depends on the population under investigation and the experience
of the reader (McCarron et al., 2009b). Petrifilm or agar-based
tests tend to involve relatively cheap equipment and reagents.
However, they require considerable user training, as well as suffi-
ciently high throughput to maintain user skills. Agar-based tests
often allow for easy visual identification of sample contamination,
which is important to monitor sample quality. Unfortunately, not
all user manuals provide guidance on the distinction between
positive and contaminated samples, or its importance. In recent
market introductions, such as Point-of-Cow and Mastatest
(Jones et al., 2019), consumables and equipment are more sophis-
ticated and more expensive to increase ease of use. Although the
test is run on-farm, data interpretation may happen off-farm,
using cloud-based computing systems. Issues around data confi-
dentiality and data ownership in such systems may need further
consideration, especially if test data is combined with data at
cow or farm level. Culture-based tests all have similar TAT of
up to 24 h. Although this is fast enough to inform decision mak-
ing, farmers would prefer less delay with turn-around from one
milking to the next (Griffioen et al., 2016).
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Culture independent pathogen information
Commercially available culture-independent pathogen detection
systems are currently based on polymerase chain reaction (PCR),
a method to selective amplify target DNA of interest. Targets
may be genus specific, species specific, or indicative of AMR, as
in the case of the blaZ gene encoding penicillin resistance in
Staph. aureus. DNA amplification is possible even when bacteria
are non-viable or in a viable but non-culturable state, which enables
pathogen detection in culture-negative samples. This is probably
more relevant for samples that are shipped to a laboratory than
for POC testing and use of PCR is largely limited to professional
laboratories. Whether detection of bacterial DNA in culture nega-
tive samples provides justification for AMU is an open question
(Nyman et al., 2016). Growing recognition of the existence of a
mammary microbiota, and descriptions of mastitis as a ‘dysbiosis’,
suggest that presence of DNA in low quantities may be normal.
Studies on associations between treatment and cure have historic-
ally been culture based. If or how treatment impacts on the out-
come of CM cases with PCR-positive, culture-negative results is
untested.
To combine the scientific characteristics of DNA-based testing
with the convenience characteristics of on-farm testing, loop-
mediated isothermal amplification (LAMP) of DNA is explored.
This test uses different chemistry than PCR, requires less sample
preparation, and is less sensitive to inhibitory substances present
in biological samples (Bosward et al., 2016). It can be configured
as a pregnancy test-like lateral flow device, which could be a rapid
and cost-effective on-farm diagnostic (Cornelissen et al., 2016).
LAMP has received attention in the scientific literature as a
means to make molecular diagnostics feasible and affordable in
low resource settings. Its implementation as on-farm POC test
for CM is hampered by heterogeneity of mastitis pathogens and
resistance determinants and the limited ability for multiplex test-
ing. The latter may be addressed through developments in micro-
fluids (see Future developments).
Future developments
Technological development progresses extremely quickly, demon-
strated by revolutionary changes in computing, mobile phone
technology, and DNA-sequencing over recent decades. The biol-
ogy of CM in dairy cattle has not changed as much over the same
period, although developments in genetics and husbandry have
led to significant shifts in milk production and predominant
pathogen populations in developed countries. Societal attitudes
towards AMU have changed more recently and influence avail-
ability and use of antimicrobials for CM treatment. Possibly
most resistant to change is human behaviour, which drives the
need for as well as the development and uptake of diagnostics.
In this section, we discuss opportunities to harness the power of
the technological revolution, the data revolution, and the people
that milk or manage cows (Fig. 1).
Harnessing the power of technology
Advances in microfluidics allow development of technologies that
can be incorporated into automatic monitoring systems and port-
able devices for sensitive and rapid mastitis diagnostics (Viguier
et al., 2009). After somatic cell count, perhaps biomarkers such
as acute phase proteins (APPs) are the most widely studied
inflammatory biomarkers in milk. Haptoglobin (Hp) and milk-
amyloid A (MAA) are especially prominent members of this
group in dairy cattle and both are synthesised locally in mammary
tissue. To inform treatment decisions, biomarker patterns would
need to be pathogen-specific. Whilst there is some evidence to
support this approach, which could be enhanced by multiplex
assays linked to machine learning technology (see next section),
it is not always clear whether APP profiles reflect severity of
inflammation or causative agents and concerns exist about sensi-
tivity and specificity (Pyörälä et al., 2011). Small inflammatory
mediators such as cytokines and chemokines have shown signifi-
cant promise with proteomic platforms differentiating the host
response to different pathogens (Kusebauch et al., 2018), and pro-
gress is being made in the development of biosensors for detecting
such biomarkers (reviewed by Martins et al., 2019). Increasingly,
the line between biomarker detection and pathogen detection is
blurred, as culture-free pathogen detection becomes feasible on
microfluidic devices popularly known as ‘lab on a chip’. One of
the key challenges in the development of such devices is the
need to detect multiple targets. We are not aware of developments
aimed at differentiating gram-positive and other causes of mas-
titis, although identification of a few major gram-positive mastitis
pathogens might suffice to support on-farm treatment decisions.
If so, paper-based multiplex LAMP assays may provide a low-cost
option that is fast, microbiologically safe (no pathogen amplifica-
tion, paper can be burned after use) and environmentally sustain-
able (Reboud et al., 2019).
Harnessing the power of data
Technological developments should be accompanied by develop-
ments in data analysis to maximise the benefit from increasingly
sophisticated biomarker or pathogen detection systems.
Machine learning methods became popular for many applica-
tions in which predictive performance is the main aim. This
type of narrow artificial intelligence has been applied to mastitis
diagnosis, focusing on real-time detection from milking data.
Artificial neural networks (ANN) and tree based models perform
best in this context (Ebrahimie et al., 2018; Ebrahimi et al., 2019),
linking parameters such as milk yield, electrical conductivity, and
lactose level to SCM. This black-box type of model is optimised
for prediction at the cost of interpretability, which is a good trade-
off for real-time mastitis diagnosis. Adding more layers of weights
to ANNs gives rise to the ‘deep learning’ models that are success-
ful in many fields. Dhoble et al. (2019) recommends neural net-
works also for label-free flow cytometry data to routinely screen
for mastitis.
By contrast, simple classification tree models are easy to inter-
pret, and cut-off values calculated from them are easily applicable
in POC tests such as lateral flow immunoassays. More complex
models (random forests, gradient boosted trees) gain predictive
accuracy at the cost of interpretability (Ebrahimi et al., 2019).
Like neural networks, complex tree models are mostly black
boxes to the user. Machine learning methods are more flexible
than classic multivariate statistical methods, requiring fewer
assumptions about the data generating mechanisms and inde-
pendence of various measurements. They can combine multiple
data types into a single prediction model, making them useful
for mastitis diagnosis based on a combination of demographic,
epidemiological, milking, flow cytometry, and biomarker data.
However, the lack of human oversight in the model specification
process is also the drawback of many machine learning models.
Biases in the data on which these models are trained tend to
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get reinforced in the model fitting process, reducing the applic-
ability of the model to the wider animal/farm population.
Training data sets should therefore be representative of the target
population, and also relatively large to avoid overfitting.
In the era of cheap sensors, the goal will be to develop rapid
(semi-)automated diagnostic systems that apply artificial intelli-
gence to real-time data streams (e.g. from automated milking)
and biomarker information to distinguish between gram-positive
and gram-negative pathogens. Differences in baseline parameters
between farms will pose a challenge, which can be overcome by
either standardising the machine learning models, or retraining
them for use on new farms (Ebrahimi et al., 2019). Ideally, data
from diagnostic systems would be combined with prognostic fac-
tors, such as duration of infection (SCC and CM history), parity,
as well as measures of cow value (genetic merit and lactational
performance) to weigh the probability of treatment success
against the value of the individual animal. Studies on prognostic
indicators are limited but suggest the importance of similar fac-
tors across multiple gram-positive organisms (Barkema et al.,
2006, Samson et al., 2016).
Harnessing the power of people
Scientific research has generated sufficient knowledge to support
targeted treatment of non-severe CM based on pathogen identifi-
cation and cow factors. However, this knowledge is hardly imple-
mented and farmers frequently experience ‘insecurity’ and
‘uncertainty’ about mastitis treatment (Swinkels et al., 2015).
Such feelings may motivate farmers to seek social approval and
emulate peer behaviour, for example by extending treatment
where increased AMU is perceived to be ‘better’ (Swinkels
et al., 2015). Ideally, the same social phenomenon would be har-
nessed to reduce AMU, e.g. by training ‘champions’ of antimicro-
bial stewardship and using peer networks to spread prudent
AMU. Farmer-led approaches rather than traditional passive
knowledge transfer methods may be the best way to motivate
change in AMU or POC test use (Bard et al., 2017). In addition,
communication approaches like motivational interviewing, which
are designed to facilitate clients’ internal motivation to change
may improve uptake of veterinarian advice (Bard et al., 2019;
Svensson et al., 2019). Demographic factors and affective attri-
butes, such as a veterinarian’s age, respectfulness and dominance,
or a farmer’s education level also influence farmers’ satisfaction
and willingness to adopt veterinary advice (Ritter et al., 2019).
Such insight could be implemented to promote POC tests uptake
and targeted treatment approaches.
Farmers and veterinarians are part of food production and
health care systems that may provide barriers or incentives for
behaviour change. Perceived barriers at farm level include lack
of time, economic investment with no financial short-term bene-
fits and labour shortages (Ritter et al., 2017). Drivers for uptake
may include improvement of cows’ welfare and farm profitability,
long-term job satisfaction, reputational benefits in relation to con-
sumer demands, social recognition and pride, and the desire to
Fig. 1. Point-of-care tests for bovine clinical mastitis. What do we have and what do we need.
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conform to perceived standards of ‘being a good farmer’ (Swinkels
et al., 2015). In some countries AMU quota have been implemen-
ted successfully or recommended to reduce AMU (Bos et al.,
2015; O’Neill, 2016). Benchmarking of individual AMU against
average AMU of peers or at national level can provide a sense
of being part of a nationwide reduction campaign and may
encourage POC test uptake, as farmers are more inclined to
assume their responsibility as a part of joint effort (Ritter et al.,
2017). It would be naïve, however, to ignore the role of commer-
cial drivers in uptake of selective treatment to reduce AMU. Many
veterinarians generate income from sales of antimicrobials, and
this may serve as a disincentive for promotion of targeted treat-
ment. In many countries, antimicrobial use and sales are not
under veterinary control, which makes the issue even more com-
plicated. Contracts and demands from milk processors and retai-
lers may override preferences or recommendations from farmers
and veterinarians. The balance between ‘stick’ (forced reduction
in AMU) and ‘carrot’ (financial and reputational benefits from
reduction in AMU) will differ between countries and production
systems and change over time.
Final thoughts
The 3Rs of Reduction, Refinement and Replacement are well
known in the context of experimental animal research. The
same concepts could be applied to antimicrobial treatment of
mastitis. Reduction can be achieved if AMU for non-severe CM
is targeted to gram-positive IMI only. As reviewed here, this
may require further improvements in convenience characteristics
and scientific criteria of POC tests and changes in knowledge, atti-
tudes and behaviours among veterinarians and dairy farmers.
Behaviour change should also include refinement, whereby we
should abstain from the use of HP-CIA in dairy cattle (Turner
et al., 2018). Professionals in the dairy industry, processors, retai-
lers, pharmaceutical companies and regulators all have a role to
play in reduction and refinement as they buy milk, or produce,
approve and market antimicrobial products. Ideally, refinement
of herd management practices would reduce the incidence of
mastitis and the need for treatment. The concept of replacement
is used in dry cow treatment, where internal teat sealants increas-
ingly replace antimicrobials as tools for infection prevention. To
some extent, anti-inflammatory and supportive therapy can act
as replacements in treatment of lactational CM. They are not
causative in removing the infectious agent but contribute to a suc-
cessful host response. Alternatives that target mastitis pathogens,
such as biocins and phage therapy, require further development
(reviewed by Angelopoulou et al., 2019).
Regardless of the need for further research on replacement, we
already have the tools and the knowledge to reduce and refine the
use of antimicrobials in treatment of lactational mastitis. The onus
is on the veterinary profession, the farming industry, and asso-
ciated industries and regulators to decide how best to incentivise
and implement them.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S002202992000062X
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